Efficacy observation of compound Xiatianwu combined with methotrexate and hydroxychloroquine in treatment of rheumatoid arthritis
Objective To analyze the efficacy and safety of Chinese medicine compound Xiatianwu combined with methotrexate(MTX)and hydroxychloroquine(HCQ)in treatment of patients with rheumatoid arthritis(RA).Methods Eighty RA patients admitted to Zhejiang Provincial People's Hospital from January 2020 to December 2022 were divided two groups with 40 cases in each group:patients in study group were treated with compound Xiatianwu tablets,MTX and HCQ,patients in control group were treated with MTX plus HCQ.The clinical efficacy and laboratory indices before and after treatment in two groups were compared.Results The ApoA1 and HDL-C levels of the study group after treatment were increased compared to those before treatment,and also were higher than those of the control group;the atherosclerosis index(Al)of the study group was declined after treatment,and also lower than that of the control group(all P＜0.05).The CRP,ESR,and anti-CCP levels of the study group were decreased after treatment,and also lower than those of the control group(all P＜0.05).The positive rates of RF,AKA and APF antibodies,the levels of WBC and Gib in the study group were lower than those before treatment(all P＜0.05).There were no obvious adverse reactions occurred in either groups.Conclusion Chinese medicine compound Xiatianwu tablets combined with western medicine show a better control effect on inflammation with good safety in treatment of RA patients,and can also improve dyslipidemia to reduce the risk of cardiovascular disease,which is worth promoting the clinical application.
万方数据
维普
